Skip to main content
Research and Development

Alert Coronavirus / COVID-19

If you have a new continuous cough, a high temperature, or a loss or change to your sense of taste or smell, do not come to our hospitals. Follow the national advice on coronavirus (COVID-19).

Please find information on our services and visiting restrictions in our COVID-19 section.

Please see our latest guidance on face masks.

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Serious breaches

Serious breaches of GCP or the Protocol

The MHRA have a definition of a serious breach of GCP: a 'serious breach' is a breach that is likely to affect to a significant degree:

  • the safety or physical or mental integrity of the participants; or
  • the scientific value of the trial.

In the event that a serious breach is suspected, the OUH R&D Department must be contacted so that an investigation of the concern can be undertaken as a matter of urgency.

The Clinical Trials regulations state that the Sponsor is required to report serious breaches to the REC, and MHRA (where applicable) within seven days of becoming aware of the breach.

OUH R&D can provide information on what should, or should not, be classified as a serious breach and on the practical arrangements for notifications.

The Regulations define 'serious breaches' as any serious breach of: